Oncologists Anticipate Improved Lymphoma Subtyping MDx as Targeted Drugs Approach the Clinic | GenomeWeb

NEW YORK (GenomeWeb) – More than a decade after the first studies demonstrating that diffuse large B-cell lymphomas are actually made up of two molecularly distinct subtypes with different prognoses and drug sensitivities, the incorporation of molecular testing into the treatment of DLCBL has remained largely theoretical and experimental.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.